Fig. 3From: Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyOverall survival relative to SHERBOC eligibility status. Kaplan–Meier curves for overall survival (OS–1TL) in the therapy line before possible SHERBOC inclusion, relative to SHERBOC eligibility statusBack to article page